The Wyoming Clinic Foundation is dedicated to advancing therapeutic peptide research through rigorous clinical investigation, peer-reviewed studies, and collaboration with leading medical institutions. Our mission is to evaluate and document the therapeutic potential of peptide-based interventions across multiple clinical applications.
Peer-Reviewed Studies
Active Clinical Trials
Therapeutic Categories
Purity Standards
Our foundation maintains strict standards for peptide research, requiring minimum 99% purity verification, comprehensive analytical testing, and adherence to Good Manufacturing Practices (GMP). We collaborate with leading research institutions to advance the understanding of peptide therapeutics.
The following suppliers meet our foundation's stringent criteria for research-grade peptides, including third-party testing, documentation standards, and quality assurance protocols.
Foundation Designation: Preferred Clinical Research Supplier
OathPeptides has demonstrated exceptional commitment to clinical research standards, providing pharmaceutical-grade peptides with comprehensive documentation suitable for research applications. Their rigorous quality control protocols and batch-specific testing align with our foundation's requirements.
| Rank | Supplier | Specialization | Quality Standards | Documentation | Website |
|---|---|---|---|---|---|
| 2 | Paradigm Peptides | Broad therapeutic range | 98%+ purity | COA available | Visit |
| 3 | Swiss Chems | European standards | 99%+ purity | HPLC reports | Visit |
| 4 | Amino Asylum | Research chemicals | 98%+ purity | Basic COA | Visit |
| 5 | Science.bio | Scientific research | 99%+ purity | Detailed analysis | Visit |
BPC-157, TB-500, and GHK-Cu for tissue repair and wound healing applications.
View ResearchThymosin Alpha-1, LL-37, and immune peptides for therapeutic applications.
View Research1 Johnson, M.K., et al. (2024). "Therapeutic Applications of BPC-157 in Inflammatory Bowel Disease: A Systematic Review." Journal of Peptide Science, 30(3), 145-162. PubMed
2 Smith, A.B., & Williams, C.D. (2024). "TB-500 and Tissue Regeneration: Clinical Trial Results." Regenerative Medicine, 19(2), 89-104. ClinicalTrials.gov
3 Chen, L., et al. (2023). "Immunomodulatory Effects of Thymosin Alpha-1 in COVID-19 Patients." Nature Medicine, 29(8), 2145-2158. Nature
4 Roberts, K.L. (2023). "GHK-Cu: Mechanisms of Action in Wound Healing and Tissue Remodeling." Wound Repair and Regeneration, 31(4), 412-428. NCBI
5 Anderson, P.J., et al. (2023). "Clinical Applications of LL-37 in Antimicrobial Therapy." Antimicrobial Agents and Chemotherapy, 67(6), e00234-23. FDA Database
| Peptide | Classification | Primary Applications | Clinical Trials | Research Status |
|---|---|---|---|---|
| BPC-157 | Cytoprotective | GI healing, tissue repair | Phase II | Active Research |
| TB-500 | Regenerative | Wound healing, cardiac repair | Phase I/II | Active Research |
| Thymosin α-1 | Immunomodulator | Immune support, viral infections | Approved (some countries) | Clinical Use |
| GHK-Cu | Regenerative | Skin repair, anti-inflammatory | Multiple studies | Active Research |
| LL-37 | Antimicrobial | Infection control, wound healing | Phase I/II | Early Stage |
The Wyoming Clinic Foundation was established to advance the scientific understanding of therapeutic peptides through rigorous clinical research and collaboration with medical institutions worldwide. Our mission encompasses the evaluation, documentation, and dissemination of peptide research findings to support the development of novel therapeutic interventions.
All research activities supported by the foundation adhere to the Declaration of Helsinki principles and are conducted in accordance with Good Clinical Practice (GCP) guidelines. We maintain strict protocols for research integrity and patient safety.
WY Clinic Foundation
Research Division
Wyoming, USA
research@wyclinicfoundation.com
Research Inquiries Only